Retinal Neovascularization
14
1
1
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
7.1%
1 terminated out of 14 trials
88.9%
+2.4% vs benchmark
14%
2 trials in Phase 3/4
0%
0 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (14)
Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin
Longterm Efficiency and Safety of Intravitreal Injections With Bevacizumab in Patients With Neovascularisation or Macular Edema
Home OCT Guided Management Study of Subjects Diagnosed With Neovascular-AMD
Selective Retinal Pigment Epithelium Laser Therapy for Macular Disease of the Retina
High Resolution Optical Coherence Tomography
Daily Testing at Home by NV-AMD Subjects With Notal Home OCT.
Study of the Modification of the Retinal Nerve Fiber Layer in Patients Treated With Intravitreous Injection of Anti-VEGF
Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection
Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)
Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration
Squalamine for the Treatment in Proliferative Diabetic Retinopathy
Panretinal Photocoagulation (PRP) Plus Ranibizumab for Proliferative Diabetic Retinopathy
Intravitreal Avastin in Proliferative Retinopathies
Krypton-Argon Regression of Neovascularization Study (KARNS)